TEVA-FUROSEMIDE 80 MG
FUROSEMIDE : 80 MG · DIN 00765953 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-FUROSEMIDE?
TEVA-FUROSEMIDE 80 MG contains FUROSEMIDE : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 00765953, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Jul-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-FUROSEMIDE used for?
TEVA-FUROSEMIDE (furosemide) is indicated for: • The treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease including, nephrotic syndrome, as well as other edematous states amenable to diuretic therapy. • Can also be used alone in the control of mild to moderate hypertension, or in combination with other antihypertensive agents in more severe cases. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controllable with furosemide alone.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00765953 |
|---|---|
| Brand name | TEVA-FUROSEMIDE |
| Generic / active ingredient | FUROSEMIDE : 80 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 80 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C03CA01 FUROSEMIDE |
| AHFS class | 68:20.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Jul-2012 |
| Original market date | 1990-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is FUROSEMIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C03CA01 FUROSEMIDE. 21 of 73 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FUROSEMIDE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 00396788 |
| APO-FUROSEMIDE | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 00362166 |
| APO-FUROSEMIDE | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 00707570 |
| FUROSEMIDE INJ USP | 10 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00527033 |
| FUROSEMIDE INJECTION SDZ | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02382539 |
| FUROSEMIDE INJECTION USP | 10 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02461404 |
| FUROSEMIDE INJECTION USP | 10 MG | SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02480530 |
| FUROSEMIDE INJECTION USP | 20 MG / 2 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02384094 |
| FUROSEMIDE INJECTION, USP | 10 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02535882 |
| FUROSEMIDE SPECIAL INJECTION | 250 MG / 25 ML | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02527499 |
Who else supplies FUROSEMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FUROSEMIDE appears in 291 registered pack listings across 14 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.